Paradigm Capital holds 4.01M shares of Integra LifeSciences (IART)
Rhea-AI Filing Summary
Integra LifeSciences Holdings Corp ownership disclosure: Paradigm Capital Management, Inc. reports 4,012,698 shares of Common Stock, representing 5.16% of the class as of 03/31/2026. The filing states these securities are owned by advisory clients and Paradigm has sole voting and dispositive power over these shares.
Positive
- None.
Negative
- None.
Insights
Passive institutional stake above the 5% reporting threshold.
Paradigm Capital Management, Inc. reports beneficial ownership of 4,012,698 shares (5.16%) of Integra LifeSciences Common Stock as of 03/31/2026. The filing identifies sole voting and dispositive power for those shares.
The disclosure notes the shares are owned by advisory clients rather than the firm itself; this is a common structure for investment advisers and signals aggregated client holdings crossing the 5% reporting threshold. Subsequent filings may show changes if advisory clients rebalance.
Schedule 13G filing is a routine regulatory disclosure for passive investors.
The filing is a Schedule 13G disclosure signed by the reporting person’s CCO on 05/15/2026, referencing holdings as of 03/31/2026. It states ownership is on behalf of advisory clients, consistent with passive investor reporting conventions.
Careful readers should note the filing attributes sole voting and dispositive power to Paradigm for these shares; voting/control mechanics are disclosed verbatim in the text.
Key Figures
Key Terms
Schedule 13G regulatory
Beneficially owned financial
Sole dispositive power regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.